

## Product datasheet for **TR303389**

### **LZTS1 Human shRNA Plasmid Kit (Locus ID 11178)**

#### **Product data:**

Product Type:	shRNA Plasmids
Product Name:	LZTS1 Human shRNA Plasmid Kit (Locus ID 11178)
Locus ID:	11178
Synonyms:	F37; FEZ1
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	LZTS1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 11178). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	<a href="#">NM_021020</a> , <a href="#">NM_021020.1</a> , <a href="#">NM_021020.2</a> , <a href="#">NM_021020.3</a> , <a href="#">BC075006</a> , <a href="#">BC075006.2</a> , <a href="#">BC075007</a> , <a href="#">NM_001362884</a> , <a href="#">NM_021020.5</a>
UniProt ID:	<a href="#">Q9Y250</a>
Summary:	This gene encodes a tumor suppressor protein that is ubiquitously expressed in normal tissues. In uveal melanomas, expression of this protein is silenced in rapidly metastasizing and metastatic tumor cells but has normal expression in slowly metastasizing or nonmetastasizing tumor cells. This protein may have a role in cell-cycle control by interacting with the Cdk1/cyclinB1 complex. This gene is located on chromosomal region 8p22. Loss of heterozygosity (LOH) in the 8p arm is a common characteristic of many types of cancer. [provided by RefSeq, Nov 2009]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).